Powered by
Siamab Therapeutics Announces Publication of New Preclinical Data in the Journal mAbs Describing its Novel Monoclonal Antibody Approach to Targeting the Tumor-Associated Carbohydrate Antigen STn

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the publication of new preclinical data describing its novel ST1 antibodies targeting, with high affinity and specificity, the Sialyl-Thomasen-nouveau antigen (STn), a tumor-associated carbohydrate antigen (TACA). As antibody drug conjugates (ADCs), these selective anti-STn antibodies possess potent anti-tumor activity in in vitro and in vivo preclinical cancer models. The paper, title

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox